Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian cancer: a Gynecologic Oncology Group study.

Abstract

The Gynecologic Oncology Group performed a Phase II study to determine the response rate of pyrazoloacridine (PZA) in patients with platinum-resistant ovarian cancer. PZA was administered at a dose of 750 mg/m2 intravenously over 3 hours every 3 weeks. Among 24 evaluable patients, there was 1 (4.2%) complete and 1 (4.2%) partial response. The major toxicities were hematologic. With the dose and schedule used, PZA had only modest activity in this population.

• Authors: Steven C Plaxe, John A Blessing, Mark A Morgan, John Carlson, Gynecologic Oncology Group
• Journal: American journal of clinical oncology (Am J Clin Oncol) Vol. 25 Issue 1 Pg. 45-7 (Feb 2002) ISSN: 0277-3732 [Print] United States
• PMID: 11823695 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Acridines
• Antineoplastic Agents
• Pyrazoles
• Carboplatin
• NSC 366140
• Cisplatin

Topics

• Acridines (administration & dosage, therapeutic use)
• Adult
• Aged
• Antineoplastic Agents (administration & dosage, therapeutic use)
• Carboplatin (therapeutic use)
• Cisplatin (therapeutic use)
• Drug Resistance, Neoplasm
• Female
• Humans
• Middle Aged
• Ovarian Neoplasms (drug therapy)
• Pyrazoles (administration & dosage, therapeutic use)